1. Home
  2. ARQT

as 05-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Founded: 2016 Country:
United States
United States
Employees: 296 City: WESTLAKE VILLAGE
Market Cap: 1.1B IPO Year: 2020
Target Price: $28.14 AVG Volume (30 days): 3.7M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.80 EPS Growth: N/A
52 Week Low/High: $1.76 - $13.17 Next Earning Date: 05-14-2024
Revenue: $106,394,000 Revenue Growth: 1545.18%
Revenue Growth (this year): 80.15% Revenue Growth (next year): 103.24%

Share on Social Networks:

Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Edwards Larry Todd ARQT SVP Chief Commercial Officer May 16 '24 Sell $8.98 7,640 $68,581.99 140,360 SEC Form 4
Matsuda Masaru ARQT See Remark May 2 '24 Sell $8.74 5,016 $43,828.80 185,408 SEC Form 4
Watanabe Todd Franklin ARQT See Remarks May 2 '24 Sell $8.74 13,783 $120,433.10 860,750 SEC Form 4
Burnett Patrick ARQT See Remarks May 2 '24 Sell $8.74 9,555 $83,489.68 259,745 SEC Form 4
Matsuda Masaru ARQT See Remark Mar 4 '24 Sell $11.12 3,760 $41,815.71 190,424 SEC Form 4
Burnett Patrick ARQT See Remarks Mar 4 '24 Sell $11.12 4,782 $53,181.58 269,300 SEC Form 4
Watanabe Todd Franklin ARQT See Remarks Mar 4 '24 Sell $11.12 14,903 $165,739.24 874,533 SEC Form 4
Heron Patrick J ARQT Director Mar 4 '24 Buy $9.50 21,052 $199,994.00 8,785,284 SEC Form 4
Watanabe Todd Franklin ARQT See Remarks Feb 28 '24 Sell $10.60 2,465 $26,129.00 889,436 SEC Form 4
Burnett Patrick ARQT See Remarks Jan 2 '24 Sell $3.54 1,325 $4,691.56 57,032 SEC Form 4
Matsuda Masaru ARQT See Remark Nov 18 '23 Sell $1.98 1,850 $3,661.15 46,634 SEC Form 4
Watanabe Todd Franklin ARQT See Remarks May 31 '23 Buy $6.38 1,463 $9,333.94 515,145 SEC Form 4